FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2933743550> ?p ?o ?g. }

• W2933743550 endingPage "182" @default.
• W2933743550 startingPage "178" @default.
• W2933743550 abstract "Epilepsy management in elderly patients is often complex because of several concomitant comorbidities that may limit the use of some antiepileptic drugs (AEDs). Levetiracetam (LEV) is a second-generation AED widely used in elderly patients with epilepsy while lacosamide (LCM), which has been recently approved in European Union (EU) as monotherapy for the treatment of focal onset seizures, is affected by a scarcity of data in such frail population. This study is aimed at assessing the efficacy and the tolerability of LCM as monotherapy in elderly patients affected by focal onset epilepsy compared with those receiving LEV.A retrospective chart review of patients aged ≥65 years suffering from focal onset seizures, with or without secondary generalization on LCM monotherapy or LEV monotherapy, was performed. Data regarding demographic characteristics, seizure type and etiology, LCM and LEV daily dose, number of lifetime AEDs, seizure frequency at baseline and at 12 months of follow-up, and seizure freedom rates were reported.In this observational retrospective study, 22 patients on LCM (10 males, 12 females, mean age: 76.23 ± 7.5) and 24 patients on LEV (10 males, 14 females, mean age: 73.58 ± 6.39) were enrolled. Mean LCM daily dose was 204.51 ± 88.51 mg and mean LEV daily dose was 1281.25 ± 378.15 mg. All patients had comorbidities on chronic treatment. At 12 months of follow-up, mean monthly seizure frequency reduced from 4.23 ± 8.53 to 0.33 ± 0.9 (p < .001) in LCM group and from 2.29 ± 6.11 to 0.2 ± 0.81 (p < .001) in LEV group. Furthermore, 16/22 (72.7%) LCM patients were seizure-free at 12 months of follow-up while seizure freedom was achieved by 17/24 (70.8%) patients in LEV group.Epilepsy management in elderly patients is often challenging. In this retrospective real-life study, the efficacy and the tolerability of LCM as monotherapy was favorable even at low doses in older patients and comparable with LEV with a high rate of long-term seizure freedom. Considering the frequent comorbidities and the risk of drug-drug interactions, LCM monotherapy may be a valuable option in elderly patients with focal onset epilepsy because of its favorable pharmacokinetic profile." @default.
• W2933743550 created "2019-04-11" @default.
• W2933743550 creator A5003122303 @default.
• W2933743550 creator A5009244024 @default.
• W2933743550 creator A5022210828 @default.
• W2933743550 creator A5027724468 @default.
• W2933743550 creator A5034377630 @default.
• W2933743550 creator A5069942848 @default.
• W2933743550 creator A5082528797 @default.
• W2933743550 creator A5088970392 @default.
• W2933743550 creator A5089506386 @default.
• W2933743550 date "2019-05-01" @default.
• W2933743550 modified "2023-10-12" @default.
• W2933743550 title "Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study" @default.
• W2933743550 cites W1607417547 @default.
• W2933743550 cites W1963797124 @default.
• W2933743550 cites W1986346573 @default.
• W2933743550 cites W2008984641 @default.
• W2933743550 cites W2028263964 @default.
• W2933743550 cites W2066622149 @default.
• W2933743550 cites W2113917522 @default.
• W2933743550 cites W2128031693 @default.
• W2933743550 cites W2133349787 @default.
• W2933743550 cites W2140945664 @default.
• W2933743550 cites W2143243043 @default.
• W2933743550 cites W2160776137 @default.
• W2933743550 cites W2556184649 @default.
• W2933743550 cites W2592509339 @default.
• W2933743550 cites W2593873339 @default.
• W2933743550 cites W2610126244 @default.
• W2933743550 cites W2747102312 @default.
• W2933743550 cites W2747829686 @default.
• W2933743550 cites W2772160666 @default.
• W2933743550 cites W2792857103 @default.
• W2933743550 cites W2793875845 @default.
• W2933743550 cites W2802306051 @default.
• W2933743550 cites W2804901880 @default.
• W2933743550 cites W2808402737 @default.
• W2933743550 cites W2885322963 @default.
• W2933743550 cites W2893789932 @default.
• W2933743550 cites W2905196766 @default.
• W2933743550 doi "https://doi.org/10.1016/j.yebeh.2019.02.022" @default.
• W2933743550 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30959275" @default.
• W2933743550 hasPublicationYear "2019" @default.
• W2933743550 type Work @default.
• W2933743550 sameAs 2933743550 @default.
• W2933743550 citedByCount "13" @default.
• W2933743550 countsByYear W29337435502020 @default.
• W2933743550 countsByYear W29337435502021 @default.
• W2933743550 countsByYear W29337435502022 @default.
• W2933743550 countsByYear W29337435502023 @default.
• W2933743550 crossrefType "journal-article" @default.
• W2933743550 hasAuthorship W2933743550A5003122303 @default.
• W2933743550 hasAuthorship W2933743550A5009244024 @default.
• W2933743550 hasAuthorship W2933743550A5022210828 @default.
• W2933743550 hasAuthorship W2933743550A5027724468 @default.
• W2933743550 hasAuthorship W2933743550A5034377630 @default.
• W2933743550 hasAuthorship W2933743550A5069942848 @default.
• W2933743550 hasAuthorship W2933743550A5082528797 @default.
• W2933743550 hasAuthorship W2933743550A5088970392 @default.
• W2933743550 hasAuthorship W2933743550A5089506386 @default.
• W2933743550 hasConcept C118552586 @default.
• W2933743550 hasConcept C126322002 @default.
• W2933743550 hasConcept C167135981 @default.
• W2933743550 hasConcept C187212893 @default.
• W2933743550 hasConcept C197934379 @default.
• W2933743550 hasConcept C2777332695 @default.
• W2933743550 hasConcept C2778139780 @default.
• W2933743550 hasConcept C2778186239 @default.
• W2933743550 hasConcept C2778375690 @default.
• W2933743550 hasConcept C2779384505 @default.
• W2933743550 hasConcept C2908647359 @default.
• W2933743550 hasConcept C71924100 @default.
• W2933743550 hasConcept C99454951 @default.
• W2933743550 hasConceptScore W2933743550C118552586 @default.
• W2933743550 hasConceptScore W2933743550C126322002 @default.
• W2933743550 hasConceptScore W2933743550C167135981 @default.
• W2933743550 hasConceptScore W2933743550C187212893 @default.
• W2933743550 hasConceptScore W2933743550C197934379 @default.
• W2933743550 hasConceptScore W2933743550C2777332695 @default.
• W2933743550 hasConceptScore W2933743550C2778139780 @default.
• W2933743550 hasConceptScore W2933743550C2778186239 @default.
• W2933743550 hasConceptScore W2933743550C2778375690 @default.
• W2933743550 hasConceptScore W2933743550C2779384505 @default.
• W2933743550 hasConceptScore W2933743550C2908647359 @default.
• W2933743550 hasConceptScore W2933743550C71924100 @default.
• W2933743550 hasConceptScore W2933743550C99454951 @default.
• W2933743550 hasLocation W29337435501 @default.
• W2933743550 hasLocation W29337435502 @default.
• W2933743550 hasOpenAccess W2933743550 @default.
• W2933743550 hasPrimaryLocation W29337435501 @default.
• W2933743550 hasRelatedWork W1995302457 @default.
• W2933743550 hasRelatedWork W2037442049 @default.
• W2933743550 hasRelatedWork W2747767288 @default.
• W2933743550 hasRelatedWork W2766553809 @default.
• W2933743550 hasRelatedWork W2792383391 @default.
• W2933743550 hasRelatedWork W2793900558 @default.
• W2933743550 hasRelatedWork W2933743550 @default.

• next